|
African Journal of Reproductive Health
Women's Health and Action Research Centre
ISSN: 1118-4841
Vol. 8, Num. 2, 2004, pp. 77-85
|
African Journal of Reproductive Health, Vol. 8, No. 2, Aug, 2004 pp.
77-85
Antenatal HIV Screening and Treatment in South Africa: Social Norms and Policy
Options
Memoona Hasnain
Department of Family Medicine, College of Medicine, University
of Illinois at Chicago, Chicago, Illinois, USA.
Correspondence: Memoona Hasnain, Director of Research,
Assistant Professor of Public Health in Family Medicine, Department of Family
Medicine (m/c 663), University of Illinois at Chicago, 1919 W. Taylor Street,
Chicago, IL 60612-7309. Tel: 1-312-996-8214; Fax: 1-312-996-2579; E-mail:
memoona@uic.edu
Code Number: rh04029
Abstract
South Africa has one of the highest prevalence of HIV and
AIDS in the world, with mother-to-child transmission being an important route
for spread of the infection. For years, AIDS scientists and activists locally
and internationally have been working desperately for the people of South Africa
to have access to treatment for HIV and AIDS. Policymakers in South Africa
have consistently maintained that HIV infection is not responsible for AIDS,
thus creating the biggest obstacle to implementation of appropriate prevention
and therapeutic programmes, including antiretroviral therapy for HIV positive
persons. Only recently, people within the government and ruling party, defying
previous policy, have agreed that antiretroviral drugs should be given to pregnant
women with HIV. The social fabric of South African society is markedly different
from that of Western countries. In this paper, the author analyses the likely
implications of antenatal testing and treatment of pregnant women in South
Africa, in light of the socio-economic and cultural status of women in that
society. (Afr J Reprod Health 2004; 8[2]: 77-85 )
Key Words: HIV screening, South Africa, pregnant
women
Résumé
Dépistage et traitement prénatals du VIH
en Afrique du Sud: normes sociales et options des politiques. L'Afrique
du Sud a une des plus hautes prévalences du VIH et SIDA du monde,
dont la transmission de la mère à l'enfant est une voie importante
pour la propagation de l'infection. Depuis des années, les scientifiques
et des activistes du SIDA sur le plan local et international, travaillent
désespéremment pour que les gens d'Afrique du Sud aient un
accès au traitement pour le VIH et le SIDA. Les décisionnaires
en Afrique du Sud ont systématiquement insisté sur le fait
que l'infection du VIH n'est pas responsable du SIDA, créant ainsi
le plus grand obstacle à la réalisation de la prévention
appropriée et des programmes thérapeutiques, y compris la thérapie
antirétrovirale pour les personnes séropositives. Très
récemment, les fonctionnaires et les membres du parti politique au
pouvoir, au mépris de l'ancienne politique, ont accepté que
les médicaments antirétroviraux soient donnés aux femmes
enceintes séropositives. Le tissu social de la société sud
africaine est remarquablement différent de celui des pays occidentaux.
Dans cet article, l'auteur fait une analyse des implications probables du
dépistage et traitement prénatals des femmes enceintes en Afrique
du Sud, à la lumière de la situation socio-économique
et culturelle des femmes dans cette société-là. (Rev
Afr Santé Reprod 2004; 8[2]: 77-85)
Introduction
The World Health Organization (WHO) estimates that, worldwide,
approximately 40 million people are living with HIV/AIDS; 22 million men, women
and children have died and 14,000 new infections are contracted every day.
Around the world, in the year 2003, the AIDS epidemic claimed an estimated
three million lives, and almost five million people acquired HIV, 700,000 of
which are children.1 The global disparities in the incidence, prevalence
and treatment access to HIV/AIDS certainly lend credence to the phrase "there
are always two sides to a coin." On the one hand, therapies exist today
to substantially improve the quality of life of those living with HIV and AIDS
in countries that can afford them. In Western countries, especially the United
States of America, concerted action by multiple stakeholders supported by political
will has shown results in curbing the epidemic. There are prevention strategies
that work, and large sums of private and public sector monies as well as mutually
rewarding private and public partnerships are being devoted to HIV/AIDS research.
Most importantly, antiretroviral drugs with proven efficacy to prevent the
transmission of HIV from mothers to their infants are available to a majority
of those in need. The successful implementation of antiretroviral therapy for
HIV positive pregnant women and their infants has led to dramatic reductions
in pediatric AIDS in the United States and Europe.2-4
The other (bleaker) side is quite pessimistic. In the developing
world, which bears the burden of more than 95% of the world's HIV infection,
the HIV/AIDS pandemic continues to rage on and there is little hope for those
afflicted. The AIDS epidemic in Africa bears little resemblance to that in
developed countries like the USA. In Africa, AIDS is not merely a medical problem;
it is inherently linked to and fed by the existing socio-economic conditions,
particularly for women. This is unlike the scenario in developed countries
where AIDS is limited to specific high-
risk groups, and brought under control
through intensive education, vigorous political action
and, most importantly, expensive drug therapy. In Africa, risk groups cannot
be defined; everyone is at risk. Through vertical transmission
from mother to infant, either before or during childbirth or via breastfeeding,
even newborns become infected.
South Africa has one of the highest HIV infection rates in
the world, even though the epidemic developed there later than in other hard-hit
countries in sub-Saharan Africa. With a population of 43.6 million, South Africa
has an adult literacy rate of 82% and urbanisation rate of 49%. In the past
decade and a half, the number of people affected by HIV/AIDS has risen significantly.
From 1985 to 2000, mortality rates rose 3.5 times among 25-29-year-old women
and two times among 30-39-year-old men.5 According to UNAIDS estimates,
more than six million South Africans (approximately one in seven) are currently
infected with HIV. The impact on the health sector is considerable. The percentage
of hospital beds occupied due to AIDS ranges from 26% to 70% for adults and
from 26% to 30% for children. Due to premature mortality, HIV/AIDS accounts
for 38% of total years of life lost, which is proportionately higher for females
(47%) than for males (33%). The impact of HIV/AIDS is expected to more than
double the burden of premature mortality by 2010.6
Despite these alarming statistics, the people of South Africa
have not had access to antiretroviral (ARV) therapy for a very long time. For
years, AIDS scientists and activists locally and internationally have been
working for the people of South Africa to have access to treatment for HIV
and AIDS. Policymakers in South Africa had consistently maintained that HIV
infection is not responsible for AIDS, thus creating the biggest obstacle to
implementation of appropriate prevention and therapeutic programmes, including
antiretroviral (ARV) therapy for HIV-positive persons.
Similar to the hurdles to HIV prevention and therapy efforts
for the general population, for a long time, the prevention message was not
widely applied to pregnant women in the country. Mother-to-child transmission
(MTCT) of HIV infection is an increasingly important route of disease transmission
in South Africa. The seroprevalance of HIV in pregnant women increased from
0.7% in 1990 to 26.5% in 2002, reaching 36.5% in KwaZulu
Natal.7-9 Thus, prevention efforts need a focus upon promoting HIV
counselling and testing and offering therapy for HIV-positive pregnant women
and their infants. For the past two years, people within the government and ruling
party, in a reversal of previous policy, have agreed that antiretroviral drugs
should be given to pregnant women with HIV. The purpose of this paper is to analyse
the likely implications of instituting antenatal HIV screening, including treatment
and substitute feeding of newborn babies of HIV positive women, in light of the
socio-economic and
cultural status of women in the South African society.
Socio-Economic and Cultural Status of Women in South African
Society
Every human being has the right to live in an environment
with minimum health risks and have access to health services that can prevent
or alleviate their suffering, treat disease and promote good health. In South
Africa, however, a majority of the female population is deprived of these basic
human rights. Women's gender and the socio-economic and cultural context in
which they live define their roles, as well as the amount of power they have
in the society. There is an imbalance in power between women and men that is
apparent in heterosexual relations as well as in the economic and social spheres
of life, with men having greater power than women. Women are economically vulnerable
because they do not have the same opportunities for education, training or
employment as men do. Social inequalities in income and employment have been
shown to be
predictors of HIV infection. Economic
difficulty is associated with greater exposure to risky
sexual experiences and sexually transmitted
diseases, reduced access to preventive and
therapeutic health information, and delayed or
absent diagnosis and treatment.10
Poverty or abandonment, or both, is forcing many women in
South Africa to sell sex in return for food for their families. In addition,
domestic violence is a reality in the lives of many women.11 A resulting
sense of fatalism often reduces women's motivation to take care of their sexual
health.12 Lack of respect for female sexual rights, poor facilities
for the affordable treatment of sexually transmitted diseases and many other
factors are contributing to the increasing incidence of HIV and AIDS in women
of childbearing age, which has a direct effect on their unborn children.10,13 To
make matters worse, for a very long time, the South African government was
not willing to provide antenatal HIV screening to pregnant women and antiretroviral
drugs for those who might test positive.14,15
Antenatal HIV Screening and Treat-ment: Issues and Implications
Globally, treatment modalities for HIV are rapidly changing
as the result of scientific research. In 1994, research evidence showed the
efficacy of zidovudine (AZT) in reducing mother-to-child transmission of HIV
when infected women received oral zidovudine during pregnancy, intravenous
zidovudine during labour, and neonates received oral zidovudine for six weeks.
Subsequently, elective cesarean section has also been shown to reduce the risk
of mother-to-child transmission of HIV. These preventive strategies, resulting
in dramatic declines in pediatric HIV and AIDS in the USA and Europe,2-4 are
costly options, and thus are not yet realistic solutions for resource-poor
countries like South Africa.
Mother-to-child transmission of HIV occurs primarily during
labour and delivery and after delivery through breastfeeding.16-18 As
an
alternative to AZT therapy, it has been found
that short course ARV regimens during the last
four weeks of pregnancy reduce MTCT rates by almost half when women refrain
from breastfeeding their newborns.19,20 Short course ARV regimes have
many advantages for resource-poor countries in terms of feasibility, adherence
and cost. For women who are diagnosed close to labour, a single dose of nevirapine,
a non-nucleotide reverse transcriptase inhibitor when administered to the HIV-infected
woman at the onset of labour and to her child within 72 hours of birth have been
found to markedly reduce the rate of HIV transmission in
newborns.21,22 Nevirapine therapy is not without potential disadvantages;
some recent evidence suggests that administering nevirapine treatment in infancy
may result in the development of resistance and greater vulnerability to infection
following HIV exposure in later life. Despite these potential adverse effects,
currently the benefits of nevirapine therapy for HIV-positive pregnant women
outweigh the risks. In many instances, for women in developing countries, who
first come to an antenatal clinic in late pregnancy or in early labour, single
dose nevirapine therapy remains the only option. Presently the World Health Organization
endorses this method as routine procedure for preventing mother-to-child transmission
in HIV high prevalence
developing countries.
Despite the evidence of ARV therapy being effective in preventing
MTCT, until recent years the South African government remained opposed to its
use. The reasons cited for this opposition included the toxicity of the drugs
and questions about their safe administration. After much urging by independent
groups like the Treatment Action Campaign (TAC), the government reluctantly
agreed to institute a pilot programme in 11 sites across the country. The pilot
programme was poorly conceived and implemented; all the sites were urban-based
and not enough to meet the needs of tens of thousand of babies born every
year. The location of the sites resulted
in unavailability of treatment for women in rural areas and litigation by TAC
on grounds of violation of constitutional rights of patients.
A first judgment in 2001 ordered the government to provide ARV therapy where
medically needed and was followed by an appeal from the government. The appeal
was turned down,
and in July 2002 a constitutional court judgment ordered the courts to make nevirapine
universally available to pregnant women infected with
HIV. This was followed in October 2002 by a
cabinet statement supporting wider access to antiretroviral therapy and the establishment
of the MTCT programme.
For any prevention effort directed at pregnant women, it
is also important to address HIV prevention needs in the general population.
It is certainly encouraging to see that despite the controversy in the debate
on the provision of antiretroviral rollout, South Africa's public HIV/AIDS
treatment programme is taking a step forward. In August 2003, the South African
cabinet finally approved the provision of ARV therapy for HIV-positive people
through the public health system and instructed the health ministry to act "with
urgency". A government special task team report stated that universal
provision of antiretrovirals would see approximately 1.2 million South Africans
on treatment by 2008, and was likely to save the lives of more than 1.7 million
people between 2003 and 2010. The plan envisaged that within a year, there
would be at least one service point in every health district across the country
and, within five years, one service point in every local municipality. In April
2004, Gauteng Province's health department announced the beginning of the rollout
of antiretroviral drugs as patients in five hospitals in Gauteng began receiving
free antiretrovirals. The indication for ARV treatment is based on clinical
assessment and CD4 cell count. The criteria for ARV initiation in adults and
adolescents, including pregnant women, are
CD4 < 200 cells/mm3 and symptomatic, irrespective of stage;
or (1) WHO stage IV AIDS defining illness, irrespective of CD4 count, and (2)
patient prepared and ready to take ARV treatment and adhere to therapy. The government
representative reported that the province hopes to treat about 100 new cases
a week,
expanding to 10,000 people within a year.
The MTCT prevention programme recom-mends using the same
eligibility criteria for pregnant women to start ARV therapy as other adults;
with the default first line regimen including nevirapine as the NNRTI (non-nucleotide
reverse transcriptase inhibitor) agent rather than efavirenz to avoid efavirenz's
potential of causing fetal abnormalities. According to the recommended policy,
all pregnant women with a CD4 count < 200 cells/mm3 should be
started on ARV after the first trimester. Those with CD4 counts between 200
and 350 cells/mm3 should be considered for initiation of ARV therapy
after the first trimester, with therapy to be continued for life. Women who
are diagnosed with HIV infection before pregnancy and become pregnant while
on ARV should continue therapy without interruption, including during the first
trimester. For pregnant women who test positive to HIV during labour, single
dose nevirapine is recom-mended.
With the change in government's stance and the resulting
change in health care scenario with regard to HIV screening and treatment being
made available to pregnant women, there are certainly opportunities to be availed.
However, when embarking on a widespread HIV screening programme for pregnant
women, there are a number of issues to be kept in mind. Asking pregnant women
to determine their HIV status exposes them to stigma and discrimination at
a time when they are most vulnerable and require the most protection. It is
a cruel reality in South Africa that individuals whose positive HIV status
is exposed are often ostracised, marginalised, abandoned and at times even
killed.23 The main
reason for this is that in the African culture,
HIV/AIDS is considered to be a sign of witchcraft and a bad omen, a myth propagated
in part by the traditional healers since they fail to treat
these cases.24
The existing imbalance in power between men and women has
serious implications for women's ability to protect themselves from infection,
to feel safe in determining their HIV status, to seek support and care when
infected, and to make choices for their own welfare independent of others.
Each of these factors has implications for the success of a vertical HIV transmission
prevention programme. To be successful, providers and counsellors must, at
a minimum, be aware of these realities. Political and economic concerns, historically
powerful patterns of gender discrimination and neglect of women's sexuality,
combined with cost and infrastructure, constitute the main obstacles to the
development and implementation of interventions to prevent and treat perinatal
HIV transmission.25,26
Breastfeeding poses another problem for pregnant women who
test positive for HIV. Research evidence shows that breastfeeding can transmit
HIV from mother to infant,27,28 with the risk of infection highest
in the early months of breastfeeding. Thus, HIV positive mothers are faced
with the issue of finding an alternate method to feed their babies. As part
of counselling in the MTCT programme in South Africa, HIV positive women are
given all the information about the risks breastfeeding may pose for transmitting
the infection to their newborns. However, in the end they are still faced with
making the final choice. This is often a difficult decision, depending
on their social circumstances; breastfeeding, like motherhood, is a strong
social norm and expectation for women in South Africa as in many developing
countries.13 Asking HIV positive women to stop breastfeeding their
babies is an issue fraught with many side effects. If preventing the child
from acquiring HIV infection were the sole
consideration, all infected mothers would
be advised to use formula feeding. This recommendation, usually given to
HIV-infected mothers in the developed countries, has to
be weighed with caution when given to mothers in poor countries who cannot afford
formula milk. Thus, current South African policy also
includes exclusive breastfeeding as an option for
women who do not wish to formula-feed. For those women who choose to formula-feed
their babies, they are asked to come for monthly check-ups and are provided formula
for up to six months.
Large multinational corporations promoting formula as the
best option for feeding babies exploit these women by providing free samples,
just enough for the women's milk to dry up. Even when formula milk is available,
the issue is further complicated by the fact that women may not have necessary
sanitation to mix formula without exposing infants to diarrhoea and other pathogens.
Hence, promoting infant formula feeding to prevent HIV without considering
the related issues might increase infant morbidity, malnutrition and mortality.29
Cost-effectiveness studies of perinatal transmission of HIV
in developed countries have shown that testing and treatment of positive cases
is cost-effective under all assumptions when compared to no testing and treatment.30-32 In
South Africa, antiretrovirals have been shown to be cost-effective for vertical
transmission prevention across a wide range of settings with or without formula
feeding interventions.33 However, the results cannot be generalised
to the whole country as the appropriateness of formula feeding is highly cost-effective
only in settings with reasonable levels of child survival and dangerous where
infant mortality is high or the protective effect of breastfeeding substantial.33
Future Directions
Keeping in mind the stark differences in culture and society
between developed countries and South Africa, effective implementation of an
antenatal HIV prevention programme
requires much more than an efficient clinic-based intervention. It requires a
broader community-based effort that acknowledges and
addresses women's needs and concerns, the needs
and concerns of their male partners, and the perspectives of the communities
in which they live. Despite all the social and cultural
barriers, the encouraging fact is that in countries in
which antiretrovirals are already being offered to pregnant women, many women
are stepping out to be tested and treated in order to protect
their unborn children.34
For a long-term solution, the foremost need is to strengthen
women's socio-economic status. Investing in women by providing them with education,
training and skills, technologies and services that are women-friendly, employment,
and social support would increase the likelihood of healthy and productive
women as well as healthy and productive children, families and communities.
Most of the women who are forced into unwanted sex and consequently into the
plague of AIDS could possibly be protected by simply having some financial
independence. HIV/AIDS prevention will be successful only when the changing
needs of women as well as men are recognised and responded to by local, national
and international policymakers.35-39
For instituting a policy to advocate formula milk for babies
of women who test positive for HIV, we must also find a way to help mothers
overcome the cultural barriers and expectations that lay a great stress upon
the role of breastfeeding in motherhood. This cannot be achieved by working
with mothers alone. Older women and the men in their communities would have
to be involved as well in order to find ways to help families and communities
understand, accept and support an infected mother's decision for substitute
feeding. Additionally, for those women who choose to formula-feed, adequate
provision of formula milk as well as education about hygienic preparation needs
to be provided.
Traditional healers play a critical role in
South African culture. They survived even strict
colonial legislation forbidding their practice.
Numerous studies document traditional healers'
enthusiasm for collaborating with biomedical health
providers and show that their activities are sustainable
as they generate their own income.40-42 For any HIV prevention programme
to succeed, collaboration with traditional healers is a key
element.43
Third world health systems usually imitate western models,
which often do not meet the needs of the people, thus creating more problems.
Hence, these models need to be modified to be effective when applied in developing
countries. There is no doubt about the lack of resources in South Africa. However,
the scientific knowledge for combating perinatally acquired AIDS in resource
poor countries is available.18,44 Thus, for South Africa, in spite
of being a low-income country, it should be possible to establish sustainable
community-based antenatal health care programmes integrated within the primary
health care system to provide the essential facilities for testing and treatment
of HIV for pregnant women. It is critical, though, that any efforts directed
at preventing mother-to-child transmission of HIV must take into account the
social determinants of HIV.45,46
In South Africa, unprotected sex, multiple sexual partners,
migration, and low status of women have contributed to the spread of the HIV/AIDS
epidemic. The drugs that can combat this deadly disease will not be available
until global pharmaceutical companies find ways to provide them inexpensively.47 Implementation
of a successful MTCT HIV prevention programme nationwide requires appropriate
delivery of counselling, testing and treatment services, improvement in health
infrastructure, training of health care workers, education and involvement
of communities, and the mobilisation of diverse stakeholders. Additional challenges include the constant change in
policies and practices relating to drug availability. The latest example is
the fact
that the use of nevirapine to prevent
mother-to-child transmission of HIV in South Africa
has come under threat after reports of
irregularities during trials of the drug in Uganda.
The antiretroviral drug could be de-registered by
the country's regulatory body, the Medicines
Control Council, after procedural flaws in the
Ugandan trial led to its manufacturer, Boehringer-Ingelheim, withdrawing an application
to have
it approved in the United States.
Thus, with the myriad variables affecting the availability
of drug therapy, the appropriate path to follow is to ensure that ARV therapy
is only one of many prevention options available to women who seek to protect
their unborn children from infection.48 The most significant option
must continue to be primary prevention because the best way to ensure that
an infant is not infected is to protect the mother herself. Aside from cost-effectiveness,
issues to consider in the introduction of antenatal HIV screening, antiretroviral
therapy and substitute feeding interventions into the South African health
care system include affordability, availability of human resources and infrastructure,
equity and acceptability.33
References
- UNAIDS. 2003. Joint United Nations Programme on HIV/AIDS
(UNAIDS) and World Health Organization (WHO) 2003. AIDS Epidemic Update
2003. Geneva: UNAIDS. http://www.unaids.org.
- Connor EM, Sperling RS, Gelber R, et al. for the Pediatric
AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant
transmission of human immunodeficiency virus type 1 with zidovudine treatment. N
Engl J Med. 1994; 331: 1173-1180.
- Simonds RJ, Steketee R, Nesheim S, Matheson P, Palumbo
P, Alger L, Abrams EJ, Orloff S, Lindsay M, Bardeguez AD, Vink P, Byers
R and Rogers M. Impact of zidovudine use on risk and risk factors for perinatal
transmission
of HIV. Perinatal AIDS Collaborative Transmission Studies. AIDS 1998;
12(3): 301-308.
- Fowler MG, Simonds RJ and Roongpisuthipong A. Update on
perinatal HIV transmission. Pediatr Clin North Am 2000; 47(1): 21-38.
- Dorrington R, Bourne D, Bradshaw D, Laubscher R and Timaeus
IM. The Impact of HIV/AIDS on
Adult Mortality in South Africa. Cape Town: Cape Town Medical Research
Council, 2001.
- 6. Bradshaw D, Groenewald P, Laubscher R, Nannan N, Nojilana
B, Norman R, Pieterse D, Schneider M, Bourne DE, Timaeus IM, Dorrington
R and Johnson L. Initial burden of disease estimates for South Africa, 2000. S
Afr Med J 2003; 93(9): 682-688.
- Department of Health. National HIV and syphilis antenatal
sero-prevalence survey in South Africa, 2002. http://www.doh.gov.za/facts/index.html.
- Schneider H and Fassin D. Denial and defiance: a socio-political
analysis of AIDS in South Africa. AIDS 2002; 16(Suppl 4): S45-51.
- Fassin D. The embodiment of inequality. AIDS as a social
condition and the historical experience in South Africa. EMBO Rep 2003;
4(Spec No): S4-9.
- Johnson L and Budlender D. HIV risk factors: a review
of the demographic, socio-economic, biomedical and behavioural determinants
of HIV prevalence in South Africa. Cape Town: Centre for Actuarial Research,
University of Cape Town, 2002.
- Jewkes R, Penn-Kekana L, Levin J, Ratsaka M and Schrieber
M. Prevalence of emotional, physical and sexual abuse of women in three
South African provinces. S Afr Med J 2001; 91(5): 421-428.
- Campbell C. Selling sex in the time of AIDS: the psychosocial
context of condom use by Southern African sex workers. Soc Sci Med 2000;
50: 479-494.
- Gupta G and Weiss E. Women's lives and sex: Implications
for AIDS prevention. Cult Med Psychiatry 1993; 17: 399-412.
- Sidley P. Clouding the AIDS issue. BMJ 2000; 320(7240):
1016.
- Magkoba M. HIV/AIDS: the perils of pseudoscience. Science 2000;
288: 1171.
- Mofenson LM. Mother-child HIV-1 transmission: Timing and
determinants. Obstet Gynecol Clin North Am 1997; 24(4): 759-784.
- Bertolli J, St Louis ME, Simonds RJ, Nieburg P, Kamenga
M, Brown C, Tarande M, Quinn T and Ou CY. Estimating the timing of mother-to-child
transmission of human immunodeficiencycvirus in a breast-feeding population
in Kinshasa, Zaire. J Infect Dis 1996; 174(4): 722-726.
- De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba
J, Hoff E, Alnwick DJ, Rogers M and Shaffer N. Prevention of mother-to-child
HIV transmission in resource-poor countries: translating research into
policy and practice. JAMA 2000; 283(9): 1175-1182.
- Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin
W, Young NL, Chotpitayasunondh T, Chearskul S, Roongpisuthipong A, Chinayon
P, Karon J, Mastro TD and Simonds RJ. Short-course zidovudine for perinatal
HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial.
Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;
353(9155): 773-780.
- Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang
S, Comeau AM, Phoolcharoen W, Essex M, McIntosh K and Vithayasai V. A trial
of shortened zidovudine regimens to prevent mother-to-child transmission
of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand)
Investigators. N Engl J Med 2000; 343(14): 982-991.
- Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito
C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler
MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F and Jackson JB. Intrapartum
and neonatal single-dose nevirapine compared with zidovudine for prevention
of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012
randomised
trial. Lancet 1999; 354(9181): 795-802.
- Owor M, Deseyve M, Duefield C, et al. The one-year safety
and efficacy of HIV-1NET 012 trial. In: XIII International AIDS Conference,
Durban, South Africa, 2000.
- Branegan J, Dowell W and Park A. The hand of death. Time 2001;
157(6): 26-54.
- Johnson D. Traditional healing and HIV/AIDS: A Central
African experience. AIDSLink 1996; 19: 39-40.
- Susser I and Stein Z. Culture, sexuality, and women's
agency in the prevention of HIV/AIDS in Southern Africa. Am J Public Health 2000;
90: 1042-1048.
- McIntyre J and Gray G. What can we do to reduce mother
to child transmission of HIV? BMJ 2002; 24: 218-221.
- Miotti PG, Taha TE, Kumwenda NI, Broadhead R, Mtimavalye
LA, van der Hoeven L, Chiphangwi JD, Liomba G and Biggar RJ. JAMA 1999;
282: 744-749.
- Nduai R, John G, mbori-Ngach D, Richardson B, Overbaugh
J, Mwatha A, Ndinya-Achola J, Bwayo J, Onyango FE, Hughes J and Kreiss
J. Effect of breastfeeding and formula feeding on transmission of HIV-1:
a randomised
clinical trial. JAMA 2000; 283: 1167-1174.
- Latham MC, Preble EA. Appropriate feeding methods for
infants of HIV infected mothers in sub-Saharan Africa. BMJ 2000;
320: 1656-1660.
- Ecker J. The cost effectiveness of human immunodeficiency
virus screening in pregnancy. Am J Obstet Gynecol 1996; 174: 716-721.
- . Immergluck LC, Cull WL, Schwartz A, Elstein AS. Cost effectiveness
of universal compared with voluntary screening for human immunodeficiency
virus among pregnant women in Chicago. Pediatrics 2000; 105: E54.
- Zaric GS, Bayoumi AM, Brandeau ML and Owens DK. The cost
effectiveness of voluntary prenatal and routine newborn HIV screening in
the United States. J Acquir Immune Defic Syndr Hum Retroviraol 2000;
25: 403-416.
- Söderlund N, Zwi K, Kinghorn A and Gray G. Prevention
of vertical transmission of HIV: analysis of cost effectiveness of options
available in South Africa. BMJ 1999; 318: 1650-1656.
- Abt Associates. The Impending Catastrophe: A Resource
Book on the Emerging HIV/AIDS Epidemic in South Africa. Abt Associates
South Africa, Inc., 2000. http://www.mrc.ac.za/urbanbulletin/june2000 /impending.htm
- Stein Z. HIV prevention: the need for methods women can
use. Am J Public Health 1990; 80: 460-462.
- Schoepf B. Women at risk: case studies from Zaire. In:
Herdt G and Lindenbaum S (Eds.). The Time of AIDS: Social Analysis, Theory
and Method. CA: Sage Publications, 1992, 259-286.
- Farmer P, Lindenbaum S and Good M. Women, poverty and
AIDS: An introduction. Cult Med Psychiatry 1993; 17: 387-397.
- Reid E. Placing women at the center of the analysis. In:
Bond G, Kreniske J, Susser I and Vincent J (Eds.). AIDS in Africa and the
Caribbean. CO: Westview Press, 1997, 159-165.
- Parker R, Barbosa R and Aggleton P (Eds.). Framing
the Sexual Subject. CA: University of California Press,
2000, 110-115.
- Staugaard F. Role of traditional health workers in prevention
and control of AIDS in Africa. Trop Doct 1991; 21: 22-24.
- Swift PJ and Strang JI. Traditional healers and AIDS prevention. S
Afr Med J 1993; 83: 690-691.
- O'Rourke N. Working together: Traditional and modern health
care practitioners and HIV/AIDS. AIDSLink 1996; 4: 22-23.
- Giarelli E and Jacobs LA. Traditional healing and HIV-AIDS
in KwaZulu-Natal, South Africa. Am J Nurs 2003; 103(10): 36-46.
- Mofenson LM and McIntyre JA. Advances and research directions
in the prevention of mother-to child HIV-1 transmission. Lancet 2000;
355(9222): 2237-2244.
- Campbell C and Mzaidume Y. How can HIV be prevented in
South Africa? A social perspective. BMJ 2002; 324(7331): 229-232.
- Fassin D and Schneider H. The politics of AIDS in South
Africa: beyond the controversies. BMJ 2003; 326: 495-497.
- Voelker Rebecca. Poor nations ravaged by AIDS need the
right resources now. JAMA 1999; 282: 1992-1994.
- Zwi K, Söderlund N and Schneider H. Cheaper antiretrovirals
to treat AIDS in South Africa: They are at their most cost effective in
preventing mother to child transmission. BMJ 2000; 320: 1551-1552.
© Women's Health and Action Research Centre 2004
|